07:34 AM EDT, 10/28/2024 (MT Newswires) -- Merck ( MRK ) and Moderna ( MRNA ) said Monday it initiated a phase 3 trial evaluating the investigational V940 in combination with Keytruda to treat certain types of non-small cell lung cancer.
The first patients in the trial were enrolled in Canada.
Price: 104.15, Change: +0.17, Percent Change: +0.16